iRhythm Holdings, Inc.
IRTC Healthcare Medical Devices
iRhythm Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $747.1 million, up 26.2% from fiscal 2024.
- Revenue
- +14.9%
- EPS
- −462.5%
- Free cash flow
- −157.6%
- Total debt
- +0.48%
Quarter to September 2026, against a year earlier
Follow IRTC
Alert me
iRhythm Holdings, Inc. (IRTC) P/B ratio
As of 5 November 2026, iRhythm Holdings, Inc. (IRTC) trades at a P/B ratio of 24.4×. Over the past ten years it has ranged from 0.0× (December 2016) to 57.7× (September 2025); the current reading is higher than 64% of that period. That is above the Medical Devices industry median of 2.5× and above the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 37.2× | 20.15% |
| FY2024 | 30.9× | 110.14% |
| FY2023 | 14.7× | 25.47% |
| FY2022 | 11.7× | (4.97%) |
| FY2021 | 12.3× | (35.92%) |
| FY2020 | 19.3× | 51.69% |
| FY2019 | 12.7× | (60.09%) |
| FY2018 | 31.8× | 94.36% |
| FY2017 | 16.4× | 856.23% |
| FY2016 | 1.7× | — |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Sep 2026 | 21.2× | 0.96% |
| Jun 2026 | 21.0× | (11.59%) |
| Mar 2026 | 23.8× | (35.99%) |
| Dec 2025 | 37.2× | (18.09%) |
| 40 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| NEOG Neogen Corporation compare | 1.2× |
| ITGR Integer Holdings Corporation compare | 2.5× |
| LIVN LivaNova PLC compare | 3.8× |
| TMDX TransMedics Group, Inc. compare | 4.3× |
| UFPT UFP Technologies, Inc. compare | 5.0× |
| AXGN AxoGen, Inc. compare | 5.4× |
| HAE Haemonetics Corporation compare | 6.2× |
| TXG 10x Genomics compare | 9.2× |
| IRTC iRhythm Holdings, Inc. | 24.4× |
| Medical Devices industry median | 2.5× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on IRTC
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement